RESEARCH TRIANGLE PARK, N.C., June 16, 2014 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) , a clinical-stage company focused on developing novel anti-infectives to address drug-resistant infections, today provided a corporate progress update and reported financial results for the quarter ended March 31, 2014.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.